Skip to content

Study · Not a test of the peptide alone · 2026

1 result

Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice.

Kubota-Okamoto S, Kubota S, Tsuchida H, Liu Y, Banno S, Imaizumi T, Fujisawa T, Takahashi Y, Kato T, Horikawa Y, Iizuka K, Murakami T and 6 more

Show all authors

Fujiwara Y, Kuwata H, Yamazaki Y, Seino Y, Tsunekawa S, Yabe D

Journal of diabetes investigation3 Feb 2026Cited by 2 (Europe PMC)

PMID41631452 (opens in a new tab)PMCIDPMC13042871 (opens in a new tab)DOI10.1111/jdi.70252 (opens in a new tab)PepBankPUB-41631452
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Efficacy outcome

    In Gipr-deficient mice, dulaglutide restored glucose-lowering effects.

    In plain wordsIn mice without functional GIP receptors, dulaglutide restored blood glucose lowering.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseGlucose lowering
    Study

    mousen: not reported in source

    Gipr knockout mice
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Importantly, dulaglutide restored glucose-lowering effects in Gipr-/- mice, confirming preserved GLP-1 receptor function.
    1 context sentence
    Summary · context
    To confirm GLP-1 pathway integrity, dulaglutide was administered to a subset of animals.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.